Despite the limitations of a single case report mentioned here, the rapid and ongoing therapy response in overcoming the acquired PD-1 resistance by adding an anti-CTLA-4 antibody may be a promising strategy for other patients with Lynch syndrome-associated CRC. Here, CTLA4 is linked to Lynch syndrome.